A Phase 1, Randomized, Partially-Blind, Parallel-Group, Active and Placebo Controlled Study to Evaluate the Safety and Pharmacokinetics of Single Oral Doses of Entecavir Extended Release (XR) in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 05 Jul 2018
At a glance
- Drugs Entecavir (Primary)
- Indications Hepatitis B
- Focus Pharmacokinetics
- Sponsors Aucta Pharmaceuticals
- 25 Jun 2018 Status changed from not yet recruiting to completed.
- 05 Oct 2017 Planned End Date changed from 13 Nov 2017 to 28 Feb 2018.
- 05 Oct 2017 Planned primary completion date changed from 6 Nov 2017 to 29 Dec 2017.